Age-related macular degeneration is the principal cause of registered legal blindness
among those aged over 65 in the United States, western Europe, Australia, and Japan …

Anatomy and physiology of the eye makes it a highly protected organ. Designing an effective
therapy for ocular diseases, especially for the posterior segment, has been considered as a …

During embryogenesis, the development and differentiation of the eye requires the
concomitant formation of the neural/glial elements along with a dense vascular network. The …

Genetic medicine is offering hope as new therapies are emerging for many previously
untreatable diseases. The eye is at the forefront of these advances, as exemplified by the …

We have performed a long-term study into the use of a lipophilic amino-acid dendrimer to
deliver an anti-vascular endothelial growth factor (VEGF) oligonucleotide (ODN-1) into the …

Nucleic acids have gained a lot of interest for the treatment of ocular diseases. The first to
enter in clinic has been Vitravene® an antisense oligonucleotide for the treatment of …

Retina has long been considered less plastic than cortex or hippocampus, the very sites of
experience‐dependent plasticity. Now, we show that retinal development is responsive to …

Antisense oligonucleotides (ODNs) specific for VEGFR-2-(17 MER) and inhibiting HUVEC
proliferation in-vitro were screened. One efficient sequence was selected and incorporated …

Ocular neovascularisation is the leading cause of blindness in developed countries and the
most potent angiogenic factor associated with neovascularisation is vascular endothelial …

Non-viral vectors for potential gene replacement and therapy have been developed in order
to overcome the drawbacks of viral vectors. The diversity of non-viral vectors allows for a …